95 related articles for article (PubMed ID: 7727864)
1. [Pharmacokinetic mechanisms of resistance to anticancer medications].
Robert J
Bull Cancer; 1994 Dec; 81 Suppl 2():78s-81s. PubMed ID: 7727864
[TBL] [Abstract][Full Text] [Related]
2. Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling.
Altinok A; Lévi F; Goldbeter A
Eur J Pharm Sci; 2009 Jan; 36(1):20-38. PubMed ID: 19041394
[TBL] [Abstract][Full Text] [Related]
3. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Lee CK; Rowinsky EK; Li J; Giles F; Moore MJ; Hidalgo M; Capparelli E; Jolivet J; Baker SD
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2158-65. PubMed ID: 16609029
[TBL] [Abstract][Full Text] [Related]
5. Drug penetration in solid tumours.
Minchinton AI; Tannock IF
Nat Rev Cancer; 2006 Aug; 6(8):583-92. PubMed ID: 16862189
[TBL] [Abstract][Full Text] [Related]
6. Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug.
Hamad I; Moghimi SM
Expert Opin Drug Deliv; 2008 Feb; 5(2):205-19. PubMed ID: 18248319
[TBL] [Abstract][Full Text] [Related]
7. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
O'Connor R; O'Leary M; Ballot J; Collins CD; Kinsella P; Mager DE; Arnold RD; O'Driscoll L; Larkin A; Kennedy S; Fennelly D; Clynes M; Crown J
Cancer Chemother Pharmacol; 2007 Jan; 59(1):79-87. PubMed ID: 16642371
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
Morris MJ; Tong WP; Cordon-Cardo C; Drobnjak M; Kelly WK; Slovin SF; Terry KL; Siedlecki K; Swanson P; Rafi M; DiPaola RS; Rosen N; Scher HI
Clin Cancer Res; 2002 Mar; 8(3):679-83. PubMed ID: 11895895
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
10. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy.
Damaraju VL; Damaraju S; Young JD; Baldwin SA; Mackey J; Sawyer MB; Cass CE
Oncogene; 2003 Oct; 22(47):7524-36. PubMed ID: 14576856
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
12. Carcinogenesis and the response of tumours to anticancer drugs.
Keith WN; Brown R
Anticancer Res; 1991; 11(5):1739-43. PubMed ID: 1768046
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
Tetef ML; Synold TW; Chow W; Leong L; Margolin K; Morgan R; Raschko J; Shibata S; Somlo G; Yen Y; Groshen S; Johnson K; Lenz HJ; Gandara D; Doroshow JH
Clin Cancer Res; 2001 Jun; 7(6):1569-76. PubMed ID: 11410492
[TBL] [Abstract][Full Text] [Related]
15. Cell resensitization after delivery of a cycle-specific anticancer drug and effect of dose splitting: learning from tumour cords.
Bertuzzi A; Fasano A; Gandolfi A; Sinisgalli C
J Theor Biol; 2007 Feb; 244(3):388-99. PubMed ID: 17074361
[TBL] [Abstract][Full Text] [Related]
16. Predicting drug response based on gene expression.
Robert J; Vekris A; Pourquier P; Bonnet J
Crit Rev Oncol Hematol; 2004 Sep; 51(3):205-27. PubMed ID: 15331079
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.
de Jong RS; Mulder NH; Uges DR; Sleijfer DT; Höppener FJ; Groen HJ; Willemse PH; van der Graaf WT; de Vries EG
Br J Cancer; 1999 Feb; 79(5-6):882-7. PubMed ID: 10070885
[TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
19. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
20. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]